Oric Pharmaceuticals, Inc.

ORIC Pharmaceuticals is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing cancer therapies designed to overcome treatment resistance. Its pipeline centers on oncology programs in hormone-dependent cancers, precision oncology, and key tumor dependencies, with development activities run from its South San Francisco headquarters.

14.13

14.13

— Oric Pharmaceuticals, Inc.
%
Clinical-stage oncology programs100% Investigational drug candidates in human clinical trials for cancer.
Preclinical discovery pipeline0% Earlier-stage internal and in-licensed programs aimed at resistance mechanisms.

ORIC does not sell commercial products today; its direct counterparties are clinical trial sites, research...

  • Clinical trial collaboratorsprimary

    Hospitals, investigators, and research networks that enroll patients and run ORIC-sponsored studies.

  • Pharmaceutical partnersprimary

    Companies such as Johnson & Johnson and Bayer that supply combination agents and support studies.

  • Licensors and biotech counterpartiessecondary

    Owners of external programs that ORIC in-licenses to expand its pipeline.

  • Future oncology patientsemerging

    Patients with resistant cancers who would use ORIC therapies if approved.

ORIC is headquartered in South San Francisco, California and operates as a U.S.-based development company...

  • •Headquartered in South San Francisco, California
  • •Clinical development and regulatory work are centered in the United States
  • •Trials may enroll patients across multiple countries and sites
  • •Future commercialization would depend on oncology markets in North America and abroad

ORIC’s strategy is to concentrate resources on a small number of differentiated oncology assets, especially ORIC-944...

01
Advance ORIC-944 through late-stage developmentshort-term

This is a lead asset in resistant prostate cancer and a core value driver.

02
Develop ORIC-114 as a precision oncology programmedium-term

It broadens the pipeline beyond hormone-dependent cancers and targets resistant mutations.

03
Use business development to expand the pipelinemedium-term

External innovation can add assets without relying only on internal discovery.

ORIC is a clinical-stage company with no commercial revenue, so its value depends heavily on successful clinical...

critical

Clinical development failure

Lead programs may not demonstrate sufficient safety or efficacy in trials.

Scope
ORIC-944, ORIC-114, ORIC-533
Materiality
high
critical

Capital dependence

The company has no revenue and must fund long development timelines.

Scope
Corporate-wide
Materiality
high
high

Third-party reliance

Trials, manufacturing, and combination studies depend on external partners and suppliers.

Scope
CROs, CMOs, licensors, pharma collaborators
Materiality
high
high

Competitive pressure

Large oncology companies can move faster, fund more studies, and reach patients sooner.

Scope
Prostate cancer and precision oncology
Materiality
high
Research and development expense recognition
Affects operating loss and comparability across periods
Stock-based compensation
Affects operating expenses and net loss
Clinical trial accruals
Affects R&D expense timing
Investment valuation and maturities
Affects balance sheet and other income

Erasca, Inc.

ERAS · Pharmaceutical Preparations

Ocean Biomedical, Inc.

OCEA · Pharmaceutical Preparations

BridgeBio Oncology Therapeutics, Inc.

BBOT · Pharmaceutical Preparations

Nuvectis Pharma, Inc.

NVCT · Pharmaceutical Preparations

NextCure, Inc.

NXTC · Pharmaceutical Preparations

ORAGENICS INC

OGEN · Pharmaceutical Preparations

: 29/04/2026